Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fate Therapeutics
(NQ:
FATE
)
3.900
+0.200 (+5.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fate Therapeutics
< Previous
1
2
3
4
Next >
The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors
January 11, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 09, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
January 06, 2023
From
The Schall Law Firm
Via
Business Wire
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
January 05, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
December 13, 2022
Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
December 12, 2022
From
GT Biopharma, Inc.
Via
GlobeNewswire
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
December 10, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
December 10, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
TheNewswire.com
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
November 07, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming Investor Conferences
November 04, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
November 03, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
November 03, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
October 24, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
October 05, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.